Crystal structure of 2-(adamantan-1-yl)-5-(3,5-dinitrophenyl)-1,3,4-oxadiazole, C18H18N4O5

C18H18N4O5, monoclinic, P21/c (no. 14), a = 11.7553(8) Å, b = 6.4876(4) Å, c = 22.3442(15) Å, β = 91.263(7)°, V = 1703.64(19) Å3, Z = 4, Rgt (F) = 0.0531, wRref (F 2) = 0.1376, T = 160 K. CCDC no.: 2173380 The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters

Crystal structure of 4-ethyl-2-{[(4-nitrophenyl)methyl]sulfanyl}-6-oxo-1,6-dihydropyrimidine-5-carbonitrile, C14H12N4O3S

C14H12N4O3S, monoclinic, P21/n (no. 14), a = 12.2777(3) Å, b = 9.4312(2) Å, c = 12.9412(2) Å, β = 107.945(2)°, V = 1425.61(5) Å3, Z = 4, R gt (F) = 0.0305, wR ref (F 2) = 0.0837, T = 160 K. CCDC no.: 2059188 The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters

Crystal structure of 4-chloro-<i>N</i>′-[(1<i>E</i>)-pyridin-3-ylmethylidene]benzohydrazide, C₁₃H₁₀ClN₃O

C13H10ClN3O, monoclinic, P21/c (no. 14), a = 19.0933(2) Å, b = 23.0910(3) Å, c = 10.6831(2) Å, β = 90.064(1)°, V = 4710.00(12) Å3, Z = 16, R gt (F) = 0.0411, wR ref (F 2) = 0.1081, T = 160 K. CCDC no.: 223377

Crystal structure of 2-({[5-(adamantan-2-yl)-2-sulfanylidene-1,3,4-oxadiazolidin-3-yl]methyl}amino)benzonitrile, C20H22N4OS

C20H22N4OS, triclinic, P (1) over bar (no. 2), a = 6.8528(3) angstrom, b = 11.3498(5) angstrom, c = 13.3896(9) angstrom, alpha = 114.083(5)degrees, beta = 104.326(4)degrees, gamma = 90.369(3)degrees, V = 914.38(9) angstrom(3), Z = 2, R-gt(F) = 0.0844, wR(ref)(F-2) = 0.2217, T = 160 K

Crystal structure of N-ethyl-4-[3-(trifluoromethyl)-phenyl]piperazine-1-carbothioamide, C14H18F3N3S

C14H18F3N3S, monoclinic, P2(1)/c (no. 14), a = 4.61919(4) angstrom, b = 29.1507(3) angstrom, c = 11.27803(10) angstrom, beta = 94.4768(8)degrees, V = 1513.99(3) angstrom(3), Z = 4, R- gt (F) = 0.0588, wR( ref )(F-2) = 0.1579, T = 160 K

Crystal structure of 4-chloro-<i>N</i>′-[(1<i>E</i>)-(2-nitrophenyl)methylidene]benzohydrazide, C₁₄H₁₀ClN₃O₃

C14H10ClN3O3, triclinic, P1 (no. 1), alpha = 4.8813(2) angstrom, b = 6.7806(2) angstrom, c = 10.3135(2) angstrom, alpha = 98.101( 2)degrees, ss = 94.174( 2)degrees,gamma= 97.612( 3)degrees, V = 333.515(18) angstrom(3), Z = 1, R-gt(F) = 0.0270, wR(ref) (F-2 )= 0.0743, T = 160 K

Crystal structure of 4-chloro-N′-[(1E)-(2-nitrophenyl)methylidene]benzohydrazide, C14H10ClN3O3

C14H10ClN3O3, triclinic, P1 (no. 1), a = 4.8813(2) Å, b = 6.7806(2) Å, c = 10.3135(2) Å, α = 98.101(2)∘, β = 94.174(2)∘, γ = 97.612(3)∘, V = 333.515(18) Å3, Z = 1, Rgt(F) = 0.0270, wRref (F2) = 0.0743, T = 160 K. CCDC no.: 224565

Should outbreak response immunization be recommended for measles outbreaks in middle- and low-income countries? An update.

Measles caused mortality in >164,000 children in 2008, with most deaths occurring during outbreaks. Nonetheless, the impact and desirability of conducting measles outbreak response immunization (ORI) in middle- and low-income countries has been controversial. World Health Organization guidelines published in 1999 recommended against ORI in such settings, although recently these guidelines have been reversed for countries with measles mortality reduction goals